CORONA · Corona Remedies Ltd · Biotechnology & Drugs
CORONA · Corona Remedies Ltd · Biotechnology & Drugs
As of 05 Nov close
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹422 Cr
Revenue YoY
PAT YoY
+30.1%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
28.2
P/S (TTM)
9.3
Sector P/E
36.3
Dividend yield
+0.5%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| CORONA (this stock) | 60.5 | 28.2 | +13.5% | +26.6% | 0.22 | +0.5% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 3q
MF
12.50% (+6.15pp)
rising 1q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| CORONA | 2026-06-17 | 3246236 | 3 | STRONG | BULK |
News timeline
- unknowneconomictimes.indiatimes.com· 27 Aug 2026, 09:59 amUp to 407% returns! 12 recently listed stocks turn multibaggers as Nifty IPO index hits 52-week high
Concalls & investor presentations
AI-generatedKey takeaway: The investor presentation from CORONA Remedies Limited, dated July 31, 2026, provided an overview of the company's performance for the quarter ended June 30, 2026. The presentation highlighted a revenue of INR 422.4 crore, reflecting a year-on-year growth of 21.9%. EBITDA was reported at INR 93.1 crore with a margin of 22.0%, and profit after tax (PAT) was INR 60.1 crore, marking a 30.1% increase. Management noted that the company ranked 26th in the Indian Pharmaceutical Market (IPM) as of June 2026, up from 27th in March 2026. The presentation also emphasized the inauguration of a new EU-GMP certified hormone manufacturing facility and the company's strategic focus on chronic therapies, which contributed approximately 73.4% of revenue in Q1 FY27. Additionally, management outlined future growth strategies, including expanding into new therapeutic areas and enhancing market share.
Management emphasized strong financial performance and growth initiatives.
Sourced from an exchange-filed presentation, dated 31 Jul 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: CORONA Remedies Limited held its earnings conference call on May 12, 2026, to discuss financial results for the fourth quarter and fiscal year ending March 31, 2026. Management reported a revenue growth of 17% for FY26, exceeding the guided range of 15%, and a PAT increase of 33%. The Indian pharmaceutical market showed double-digit growth, with CORONA outperforming the industry, achieving a ranking improvement to 27th among the top 30 companies. The company announced a 100% dividend for FY26 and highlighted the successful launch of three biosimilar products. Management discussed strategic acquisitions, including Wokadine, and emphasized a focus on chronic therapy segments, which now contribute 72% to overall revenue. The CFO noted a revenue increase to INR 1,403 crores for FY26, with a strong EBITDA margin of 20.9%. Management reiterated a commitment to 15% organic revenue growth and 20% PAT growth for FY27.
Management emphasized strong financial performance and growth opportunities.
Sourced from an exchange-filed transcript, dated 18 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Management provided an overview of CORONA Remedies Limited during the earnings conference call for Q3 and nine months ended December 31, 2025. The company reported a revenue of Rs. 342 crores for Q3 FY'26, reflecting a 15% year-over-year growth, while EBITDA grew by 20% to Rs. 83 crores. Management highlighted that CORONA is the fastest growing pharmaceutical company among the top 30 in India, with an 18.9% growth rate compared to the Indian Pharmaceutical Market's 9.6%. The company emphasized its focus on chronic and semi-chronic segments, which contribute significantly to revenue. Management also discussed strategic brand acquisitions and the upcoming launch of products from the Bayer portfolio. They noted a strong cash flow position and reaffirmed their guidance of 15% revenue growth and 20% profit after tax growth for the year.
Management emphasized strong growth and strategic initiatives during the earnings call.
Sourced from an exchange-filed transcript, dated 10 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedCORONA Remedies Limited reported strong financial performance in FY2025-26, with revenue growing at a 17% CAGR over three years and EBITDA growing at a 32% CAGR. The company expanded into biosimilars and biologics, strengthened its presence in women's healthcare, and enhanced manufacturing capacity. The auditor noted no key audit matters, and the company has no defaults in loan repayments or statutory dues. The Board highlighted the company's commitment to corporate governance, sustainability, and social responsibility.
- Revenue from operations grew at a 17% CAGR over three years, with EBITDA growing at a 32% CAGR.
- Expanded into biosimilars and biologics, enhancing addressable therapy areas.
- No defaults in loan repayments or statutory dues as of March 31, 2026.
- Auditor noted no key audit matters, indicating clean financial reporting.
- Strong corporate governance and sustainability initiatives, including energy conservation and community development programs.
Key takeaway: CORONA Remedies Limited delivered robust financial growth and strategic expansion in FY2025-26, with no material financial or compliance risks reported, supported by strong governance and sustainability practices.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
No item of a kind that needs attention was stored for this company.
Contingent Liability
2 occurrencesRecent (last 12 months)
The company has a contingent liability related to direct tax matters, with an outstanding demand against which it has paid ₹1.00 Crore and filed an appeal.
The company has a future export obligation of ₹29.69 Crores under the EPCG Scheme, which must be fulfilled by FY 2026-27 to FY 2030-31.